touchONCOLOGY met with editorial board member Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this expert interview, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the last few years. However, the levels of toxicity in these combinations can be a barrier to treatment. Finally, he talks about what he feels are some of the most interesting data at this year’s ESMO congress: the KEYNOTE-022 trial, which is the first trial to compare an anti-programmed cell death protein 1 (pembrolizumab) + a BRAF inhibitor (dabrafenib) + a MEK inhibitor (trametinib) versus BRAF + MEK inhibition alone.
1. What have been the most significant recent developments in the treatment of melanoma? (0:11)
2. What are the current unmet needs and/or the challenges you face when treating patients? (2:17)
3. What developments are you most excited about in the area of melanoma over the next few years? (3:47)
4. Which presentations/data from the ESMO 2018 congress have interested you the most? (5:22)
Speaker disclosures: Paolo A Ascierto has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Immunotherapy
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!